NASDAQ
0.70USD
-0.02 (-2.67%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.5M
P/E
—
EPS
—
Beta
1.17
52W range
0.62-13.16
Day range
0.68–0.74
Open
0.74
Prev close
0.72
Volume
105.4K
Avg volume
213.9K
Dividend
0.00
IPO
2024-02-01
https://www.prnewswire.com/news-releases/fibrobiologics-reports-second-quarter-2026-financial-results-progresses-clinical-trial-evaluating-lead-wound-care-candidate-302840401.html · 7/31/2026+0.60
https://www.globenewswire.com/news-release/2026/04/30/3285584/0/en/FibroBiologics-Reports-Q1-2026-Financial-Results-and-Provides-Corporate-Update.html · 4/30/2026+0.60
https://www.benzinga.com/news/health-care/25/12/49310901/fibrobiologics-files-new-patent-for-fibroblast-tech-to-advance-deeper-into-orthopedics · 12/10/2025+0.80
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
